Patents Assigned to Sunovion Pharmaceuticals Inc.
  • Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
    Patent number: 8772301
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: July 8, 2014
    Assignee: Sunovion Pharmaceuticals, Inc.
    Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Kerry L. Spear, Lakshmi D. Saraswat
  • [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
    Patent number: 8765760
    Abstract: Provided herein are compounds of formula (I): A-L-B??(I) and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is wherein X is (i) CR1 or N, or (ii) O or NR2, each Y is independently N or CR3, and each Z is independently N or C, wherein R1, R2 and R3 are defined in the specification; L is a linker, and B is a multicyclic ring; methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are inhibitors of phosphodiesterases and useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, e.g., neurological disorders, psychosis, schizophrenia, obesity and diabetes.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: July 1, 2014
    Assignee: Sunovion Pharmaceuticals, Inc.
    Inventors: John Emmerson Campbell, Philip Jones, Michael Charles Hewitt
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20140179682
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 26, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Pyrrolidine triple reuptake inhibitors
    Patent number: 8754117
    Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: June 17, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Jianguo Ma
  • Acetamide Stereoisomer
    Publication number: 20140135300
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE
    Publication number: 20140128474
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Thomas JERUSSI, Qun Kevin FANG, Mark G. CURRIE
  • PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
    Publication number: 20140121282
    Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Application
    Filed: January 7, 2014
    Publication date: May 1, 2014
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Jianguo MA, Seth RIBE, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, Rudy SCHREIBER, Kerry L. SPEAR
  • METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE
    Publication number: 20140121283
    Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
    Type: Application
    Filed: December 23, 2013
    Publication date: May 1, 2014
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas P. JERUSSI, Chrisantha H. SENANAYAKE, Nandkumar N. BHONGLE
  • Multicyclic compounds and methods of use thereof
    Patent number: 8710245
    Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: April 29, 2014
    Assignees: PsychoGenics Inc., Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
  • Carbonate and carbamate modified forms of glucocorticoids in combination with ?adrenergic agonists
    Patent number: 8710036
    Abstract: Compositions containing ?2 adrenergic agonists in combination with carbonates and carbamates of the formula. and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: April 29, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Mark G. Currie, Steve Jones, Paul Grover, Chris H. Senanayake, Q. Kevin Fang
  • TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20140107175
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit re-uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 17, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Liming SHAO, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • PYRROLIDINE TRIPLE REUPTAKE INHIBITORS
    Publication number: 20140073682
    Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 13, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Liming SHAO, Jianguo MA
  • Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 8669291
    Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: March 11, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
  • Acetamide stereoisomer
    Patent number: 8664441
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 4, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • PREPARATION OF CHIRAL AMIDES AND AMINES
    Publication number: 20140057990
    Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 27, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Hang Zhao, Stefan G. Koenig, Charles P. Vandenbossche, Surendra Singh, Harold Scott Wilkinson, Roger P. Bakale
  • Treatment of CNS disorders with 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
    Patent number: 8658700
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: February 25, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
  • Methods of using derivatives of (?)-venlafaxine
    Patent number: 8642662
    Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: February 4, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
  • Triple reuptake inhibitors and methods of their use
    Patent number: 8592608
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: November 26, 2013
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Method for treating a sleep disorder with a dosage form of a zopiclone or eszopiclone L-malate salt
    Patent number: 8541416
    Abstract: L-malate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: September 24, 2013
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: H. Scott Wilkinson, Richard Hsia, Tushar Misra, Kostas Saranteas, Patrick Mousaw
  • CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS
    Publication number: 20130244988
    Abstract: Compositions containing ?2 adrenergic agonists in combination with carbonates and carbamates of the formula. and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.
    Type: Application
    Filed: April 22, 2013
    Publication date: September 19, 2013
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Mark G. CURRIE, Steve JONES, Paul GROVER, Chris H. SENANAYAKE, Q. Kevin FANG